Current Studies

Study Details

Respiratory Syncytial Virus (RSV) – Janssen – Evergreen

Study Information

People aged 60 years or older are at an increased risk of developing complications, such as inflammation of the lungs or pneumonia, from a cold-like virus called RSV.

Are you aged 60 years or older? Help us find a way to prevent RSV disease.

Consider supporting research by joining the EVERGREEN Study assessing a study vaccine to prevent RSV disease and learn more about
respiratory infections. The purpose of this study is to see if the investigational study vaccine can prevent respiratory syncytial virus,
or RSV, disease.

You may be eligible to participate if you:
• are 60 years of age or older.
• can do your usual daily activities even with some interference from any health conditions.
• are able to use smartphones, tablets, and/or computers.
Additional eligibility criteria will be assessed by the study center staff. The study will last for up to 2 RSV seasons.

Qualified participants may receive the study vaccine and some study-related medical care at no cost. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine.

To learn more about the EVERGREEN Study, please visit www.EVERGREENtrial.com, or fill out the form below.

Apply to Participate

If you are interested in participating in this study, please complete the following preliminary qualification form.

We will follow-up with you after we have received your submission.

  • Study Information

  • Contact Information

  • Hidden